# Deltex Medical Group plc Q&A with CEO Ewan Phillips: Interim Results (LON:DEMG)

- Link: https://www.directorstalkinterviews.com/deltex-medical-group-plc-qa-ceo-ewan-phillips-interim-results-londemg/412735299
- Published: 2017-09-14T09:41:54+01:00
- Author: Amilia Stone

**Deltex Medical Group plc** (LON:DEMG) Chief Executive Officer Ewan Phillips caught
up with DirectorsTalk for an exclusive interview to discuss their interim results
for the six months ended 30 June 2017

 

**Q1: Now, you announced your interim results this morning, can you talk us through
the highlights?**

**A1**: The big highlights are that sales are up and that’s the first time since
2014 we’ve shown growth so that’s good. The gross margin is up significantly so 
on the consumables from 70% to 80% so that’s very good and we reduced our operating
costs by 0.3 million. So, overall, we’ve got sales growing, margins increasing, 
costs reducing and that comes through in a significant reduced loss, I think crucially
in terms of both the underlying and actual cash consumption, those are heading in
the right direction quite quickly.

 

**Q2: Can you tell us a bit more around the new products that have been launched
this year?**

**A2**: Deltex Medical have had 2 new products so far this year. To deal with the
straightforward one, for the first time we’ve got a system specifically for vets
so slightly different software, slightly different algorithms but as you know it’s
a copy of what we’ve done for humans, just tweaked the vet bit. At the moment, we’ve
got the probes there, really designed for the smaller animals, sort of large dogs
down to rabbit-size I suppose, we are experimenting with bigger animals and since
seen the most ridiculous 3.5-metre-long probe which apparently is for horses but
it seems to be twice as long as the horse! So, we’re planning in that area, that’s
a pretty simple thing, I think the plan there will be in the next year or two is
to find a specialist distributor that’s got some sort of global reach.

More importantly, back in May we released, in the UK, another cardiac output monitoring
technology, High Definition Impendence Cardiography, it’s entirely non-invasive 
and it’s perfect for your awake patient and very good in intensive care. That’s 
really important, I think, strategically because that means we’ve now got three 
technologies on the one platform, we’ve got the Oesophageal Doppler, which is our
proprietary technology, we’ve got Pulse Pressure Waveform Analysis which is quite
a good entry-level technology, that’s the one that’s most common in the market because
it’s probably the easiest to do and then we’ve got this one, the software between
the two the Impendence Cardiography. Now, that’s really important because it means
we can now go to a hospital and we can sell them, on one platform, a solution that
works from newborns through to the very old that works in the clinic on awake patients
all the way through to very sick people in intensive care. It can be used pretty
easily from fairly early-stage trainee nurses through to world-leading experts, 
the Professors and everything like that.

So, it’s a really big step forward for us, we’ve still got a few bits and pieces
to add on to it which will give a far more non-invasive option which will start 
to give more things that combine everything but the core is there. We’re moving 
from something, one technology, to certainly multiple technologies and all-round
hospital solutions so that’s a big step but we won’t really see the benefits coming
through until the beginning of the second half and the next couple of years. I’m
very excited by that and I think everyone that works for the company is very excited
about that.

 

**Q3: Broadening your product offering, what does it mean for Deltex Medical in 
the future?**

**A3**: Well, it means we can really start to become the sole supplier of haemodynamic
equipment across whole hospitals. Although the technology we’ve had and built the
company on, the Oesophageal Doppler, it’s a very sophisticated technology, in my
view it’s lots and lots and lots of patients that should have it used on them but
it does take skilled operators to do that, it’s not very good to use on awake patients,
we can’t really say we should be the sole supplier, and indeed nor can any of our
competitors. I think now if we can get this these new products offered, we can move
towards that, that gives you a lot more flexibility to how you can work with your
customers, particularly these days when most hospital systems are cash-strapped 
so they’re looking for deals that work for both parties to make things happen. At
the same time, it means you can really take these modern standards of care and move
them forward quite a lot and benefit thousands of patients in every hospital rather
than tens of hundreds.

 

**Q4: How are Deltex Medical set for the rest of 2017?**

**A4**: Well, second half is traditionally stronger so we expect to have more sales
in the second half, now that’s partly seasonal but it’s also because our international
business which sells into distributors, probably best part of half of that is done
towards the end of the year so that’s a big time for us. The international business
in the first half due to timing differences was down £0.1 million so we’d expect
to recover that and show growth so we should see quite strong growth coming through
which overall in the second half, that’s always as always, fingers crossed. That,
with the continued improvement in cash performance we’ve seen that improving in 
margins, that sort of comes through, the cost of productions.

So, we would hope that we’re getting pretty close to some very good metrics on the
underlying cash consumption in the second half.

Share on:
